With the advent of new therapies for pulmonary hypertension, the need arises to define prognostic markers that definitively predict the improvement in quality of life and survival of patients treated with these new alternatives. To date, the 6-minute walk test has been the marker most widely used to determine the benefit gained from the various treatment strategies available. However, clinical, biochemical and quality of life markers present great potential for the management of patients with pulmonary hypertension.
Hypertension; pulmonary; Exercise tolerance; Walking; Exercise tests; Exercise therapy; Hemodynamic processes; Echocardiography; Quality of life; Survival; Prognostic; Guidelines